Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Guidelines for stopping therapy in chronic hepatitis C.

Mark W Russo1, Michael W Fried

  • 1Division of Gastroenterology and Hepatology, University of North Carolina, CB#7080, Room 1111, Bioinformatics Building, Mason Farm Road, Chapel Hill, NC 27599, USA.

Current Gastroenterology Reports
|January 15, 2004
PubMed
Summary

Significant advancements in chronic hepatitis C treatment show over 50% of patients achieve viral eradication with pegylated interferon and ribavirin. Understanding early virologic response milestones helps optimize treatment and reduce adverse events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratification.

Hepatology communications·2026
Same author

A systematic review of post-liver transplantation treatment and outcomes for late T-cell mediated, chronic ductopenic, and antibody-mediated rejection.

Hepatology communications·2026
Same author

Modern Diets, Metabolic Inequity, and Race-Ethnic Disparities: Unraveling the Associations With MASLD and Cancer Risk.

Journal of gastroenterology and hepatology·2025
Same author

Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.

Gastroenterology·2025
Same author

AASLD AST Practice Guideline on adult liver transplantation: Diagnosis and management of graft-related complications.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2025
Same author

Donor-Recipient Race Mismatch Is Associated with Lower Survival After Liver Transplantation for Primary Sclerosing Cholangitis.

Journal of clinical medicine·2025

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis C treatment has seen substantial progress.
  • Pegylated interferon and ribavirin therapy achieves permanent viral eradication in over 50% of patients.
  • Therapeutic indications are expanding based on safety and efficacy data.

Purpose of the Study:

  • To define virologic milestones for managing patients during antiviral therapy.
  • To identify key determinants for continuing or discontinuing treatment.
  • To reduce adverse events in non-responding patients.

Main Methods:

  • Analysis of pretreatment hepatitis C virus genotype.
  • Monitoring of virologic response at weeks 12 and 24 of treatment.
  • Evaluation of early treatment stopping points.

Related Experiment Videos

Main Results:

  • Pretreatment genotype is a key determinant in treatment decisions.
  • Virologic response at weeks 12 and 24 accurately predicts sustained response.
  • Early identification of non-responders allows for timely treatment cessation.

Conclusions:

  • Virologic milestones are crucial for effective hepatitis C management.
  • Optimizing treatment duration based on early response reduces patient exposure to unnecessary therapy and adverse events.
  • Further research into early treatment stopping points can improve patient outcomes.